Publication | Open Access

Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2–3 trial

Non-pharmacological InterventionDisease ProgressionDiabetic NeuropathyPharmacologyClinical TrialsPharmacotherapyPharmacologic InterventionPlacebo-controlled Phase 2–3Medicine